

– Flores–Mireles A.L., Walker J.N., Caparon M., Hultgren S.J (2015). Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. *Nat. Rev. Microbiol.* doi: 10.1038/2. – Murray B.O., Flores C., Williams C., Flusberg D.A., Marr E.E., Kwiatkowska K.M., Charest J.L., Isenberg B.C., Rohn J.R. (2021). Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems. *Front Cell. Infect. Microbiol.* doi: 10.3389/3. – Subashchandrabose S., Mobley H.L. (2015). Virulence and Fitness Determinants of Uropathogenic *Escherichia coli*. *Microbiol. Spectr* doi: 10.1128/4. – Schwab S. Jobin K. Kurts C. (2017)(1977).(1983). Urinary tract infection: Recent insight into the evolutionary arms race between uropathogenic *Escherichia coli* and our immune system. *Nephrol. Dial. Transplant.* doi: 10.1093/5. – ISpaulding C.N., Hultgren S.J. (2016). Adhesive pili in UTI pathogenesis and drug development. *Pathogens.* . doi: 10.3390/6– pConover M.S., Hadjifrangiskou M., Palermo J.J., Hibbing M.E., Dodson K.W., Hultgren S.J. (2016). Metabolic requirements of *Escherichia coli* in intracellular bacterial communities during urinary tract infection pathogenesis. *mBio.* doi: 10.1128/7– Tamadonfar K.O., Omattage N.S., Spaulding C.N., Hultgren S.J.(2019) . Reaching the end of the line: Urinary tract infections. *Microbiol. Spectr.* doi: 10.1128/8– Lane M.C., Alteri C.J., Smith S.N., Mobley H.L. (2007) Expression of flagella is coincident with uropathogenic *Escherichia coli* ascension to the upper urinary tract. *Proc. Natl. Acad. Sci. USA.* . doi: 10.1073/209– Soto S.M. (2014). Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches. *Adv. Biol.* doi: 10.1155/10– Tenailon O, Skurnik D, Picard B, Denamur E (March 2010). “The population genetics of commensal *Escherichia coli*”. *Nature Reviews microbiology*8 doi: 10.1038/nrmicro2298. 11– Singleton P (19919). *Bacteria in Biology, Biotechnology and Medicine* (5th ed.). Wiley. pp. 444–54. ISBN 978–0–471–98880–9. 12– Bentley R, Meganathan R (September 1982). “Biosynthesis of vitamin K (menaquinone) in bacteria”. *Microbiological Reviews.* 46 (3): 241–80. doi: 10.1128/13. – Feng P, Weagant S, Grant M (1 September 2002). 19 May 2009. Retrieved 25 January 2007. “Enumeration of *Escherichia coli* and the Coliform Bacteria”. *Bacteriological Analytical Manual* (8th ed.). FDA/Center for Food Safety & Applied Nutrition. Archived from the original . Bartoletti R., Cai T., Wagenlehner F.M., Naber K., Bjerklund Johansen . – 14 Infection and Treatment of Urinary Tract . ) 16 0 (2 T.E. Antibiotic Stewardship. *Eur. Urol.* doi: 10.1016/15– Ong L.T. (2020). Antibiotics for complicated urinary tract infection and acute pyelonephritis: A systematic review. *World J. Clin. Infect. Dis.* Doi. 10.5495/16– Cai T., Palagin I., Brunelli R., Cipelli R., Pellini E., Truzzi J.C., Van Bruwaene S. (2020). Office–based approach to urinary tract infections in 50 000 patients: Results from the REWIND study. *Int. J. Antimicrob. Agents.* doi: 10.1016/ . . 21 17– Gonzalez M.J., Da Cunda P., Notejane M., Zunino P Scavone P., Robino L.(2019). Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic *Escherichia coli* isolated from patients with urinary tract infection. *Pahog.* . 18– Sharma K., Dhar N., Thacker V.V., Simonet T.M., Signorino– Gelo F., Knott G.W., McKinney J.D. (2021). Dynamic persistence of UPEC intracellular bacterial communities in a human bladder–chip model of urinary tract infection. *Elife.* Gpp doi: 10.7554/eLife.66481. 19– Harding C., Mossop H., Homer T., Chadwick T., King W., Carnell S., Lecouturier J., Abouhajar A., Vale L., Watson G.,(2022). et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: Multicentre, open label, randomised, non–inferiority trial. *BMJ.* 376:e068229. doi: 10.1136/ . 20.– Mazzariol A., Bazaj A., Cornaglia G. (2017). Multi–

drug-resistant Gram-negative bacteria causing urinary tract infections: A review. *J. Chemother.* doi: 10.1080/1120009X.1380395 . 21. –Lavigne J.P., Thibault M., Costa P., Combescure C., Sotto A., Cariou G., Ronco E., Lanotte P., Bruyère F., Coloby P., et al.(2016). Resistance and virulence potential of uropathogenic *Escherichia coli* strains isolated from patients hospitalized in urology departments: A French prospective multicentre study. *J. Med. Microbiol.* Doi: 10.1099/jmm.0.000247 . 22–Bandyopadhyay D., Mukherjee M. (2022). Combination of bactericidal antibiotics and inhibitors of Universal stress protein A (UspA): A potential therapeutic alternative against multidrug resistant *Escherichia coli* in urinary tract infections. *J. Antibiotics.* doi: